Cinctive Capital Management LP Raises Stake in Merck & Co., Inc. $MRK

Cinctive Capital Management LP lifted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 88.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 88,482 shares of the company’s stock after buying an additional 41,456 shares during the period. Cinctive Capital Management LP’s holdings in Merck & Co., Inc. were worth $7,426,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of MRK. DLD Asset Management LP acquired a new position in Merck & Co., Inc. in the 2nd quarter valued at $2,889,340,000. Norges Bank purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter worth $2,858,570,000. Franklin Resources Inc. boosted its holdings in shares of Merck & Co., Inc. by 23.5% during the second quarter. Franklin Resources Inc. now owns 27,032,601 shares of the company’s stock worth $2,139,901,000 after purchasing an additional 5,135,748 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Merck & Co., Inc. by 35.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 19,456,096 shares of the company’s stock worth $1,540,145,000 after purchasing an additional 5,094,088 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Merck & Co., Inc. by 9.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company’s stock valued at $4,263,991,000 after purchasing an additional 4,636,183 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Buying and Selling

In related news, CMO Chirfi Guindo sold 20,000 shares of the stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the completion of the sale, the chief marketing officer owned 80,615 shares of the company’s stock, valued at approximately $9,825,356.20. This represents a 19.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Richard R. Deluca sold 37,685 shares of the firm’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the transaction, the executive vice president owned 160,174 shares in the company, valued at $19,368,240.08. The trade was a 19.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 320,176 shares of company stock worth $38,281,735. Corporate insiders own 0.13% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Analyst Ratings Changes

Several equities analysts recently commented on MRK shares. The Goldman Sachs Group upped their target price on Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. BMO Capital Markets upgraded Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $82.00 to $130.00 in a report on Thursday, December 18th. Bank of America upped their price objective on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Morgan Stanley increased their price objective on shares of Merck & Co., Inc. from $100.00 to $102.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $126.81.

Merck & Co., Inc. Trading Down 0.3%

MRK stock opened at $115.61 on Friday. The company has a market cap of $285.84 billion, a price-to-earnings ratio of 15.88, a PEG ratio of 2.24 and a beta of 0.27. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. The business has a fifty day simple moving average of $115.26 and a 200-day simple moving average of $99.68. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same period last year, the company posted $1.72 EPS. The business’s quarterly revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities research analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.